CM24
Non-Small Cell Lung Cancer
Key Facts
About Purple Biotech
Purple Biotech Ltd. is an Israeli, NASDAQ-listed biotech focused on developing next-generation oncology therapeutics. Its mission is to counteract the primary mechanisms of cancer treatment failure—immune evasion and drug resistance—through targeted agents like the anti-CEACAM1 mAb CM24 and the dual inhibitor NT219. The company's strategy centers on advancing these clinical-stage assets in combination regimens to demonstrate proof-of-concept and unlock significant value. As a micro-cap entity, its near-term trajectory is heavily dependent on clinical readouts from its Phase 2 studies.
View full company profileAbout Purple Biotech
Purple Biotech Ltd. is an Israeli, NASDAQ-listed biotech focused on developing next-generation oncology therapeutics. Its mission is to counteract the primary mechanisms of cancer treatment failure—immune evasion and drug resistance—through targeted agents like the anti-CEACAM1 mAb CM24 and the dual inhibitor NT219. The company's strategy centers on advancing these clinical-stage assets in combination regimens to demonstrate proof-of-concept and unlock significant value. As a micro-cap entity, its near-term trajectory is heavily dependent on clinical readouts from its Phase 2 studies.
View full company profileTherapeutic Areas
Other Non-Small Cell Lung Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Pepinemab (VX15/2503) | Vaccinex | Phase 1b/2 |
| GC-001 | Genocury Biotech | Preclinical |
| Immunomodulator Platform | OmniCyte | Research |
| VisAcT (18F-AraG) Imaging in NSCLC | CellSight Technologies | Phase 2 |
| VNX-208 | Vironexis Biotherapeutics | Preclinical |
| AIC100 | AffyImmune Therapeutics | Pre-clinical/Planned |
| Lung (NSCLC) PD-L1 | Mindpeak | Commercial |
| Tiragolumab | Chugai Pharmaceutical | Phase III |
| SHR-1701 | Jiangsu Hengrui Medicine | Phase II/III |
| Acasunlimab (DuoBody-PD-L1x4-1BB) | Genmab | Phase 2/3 |
| VAC2 | Lineage Cell Therapeutics | Phase 1 |